Russell J. Wiese

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Mitogen-activated Protein Kinase Kinase Inhibition Does Not Block the Stimulation of Glucose Utilization by Insulin

Dan Lazar, Russell J. Wiese, Matthew Brady et al. · Journal of Biological Chemistry · 1995 · 399 citations · Full text

The Cardiac Tissue-Restricted Homeobox Protein Csx/Nkx2.5 Physically Associates with the Zinc Finger Protein GATA4 and Cooperatively Activates Atrial Natriuretic Factor Gene Expression

Youngsook Lee, Tetsuo Shioi, Hideko Kasahara et al. · Molecular and Cellular Biology · 1998 · 273 citations · Full text

Cardiac Muscle, Cardiomyopathy, Molecular Physiology +15

The Transcription Factor GATA4 Is Activated by Extracellular Signal-Regulated Kinase 1- and 2-Mediated Phosphorylation of Serine 105 in Cardiomyocytes

Qiangrong Liang, Russell J. Wiese, Orlando F. Bueno et al. · Molecular and Cellular Biology · 2001 · 263 citations · Full text

Cardiac Muscle, Transcriptional Regulation, Cardiomyopathy +15

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó et al. · The Lancet Diabetes & Endocrinology · 2022 · 252 citations · Full text

Metabolic Syndrome, Diabetes Management, Insulin Management +8